Defining a new era of oligonucleotides

Defining a new era of oligonucleotides

We are a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases.

We aspire to develop best-in-class medicines across multiple therapeutic modalities using PRISM TM, our proprietary discovery and drug development platform that enables the precise design, optimization and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, we are targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future.

Innovative Platform

Foundation of Neurology Programs

Clinical Development Expertise

GMP Manufacturing

 

Investor Relations

Recent News

Jun 14, 2022

Wave Life Sciences Announces Pricing of $70.0 Million Underwritten Offering

CAMBRIDGE, Mass. , June 14, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today the pricing of an underwritten offering (the “Offering”)

Recent News

Jun 14, 2022

Wave Life Sciences Announces Pricing of $70.0 Million Underwritten Offering

CAMBRIDGE, Mass. , June 14, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today the pricing of an underwritten offering (the “Offering”)
Recent News and Events

Data Provided by Refinitiv. Minimum 15 minutes delayed.